A
Back in growth mode
Agilent Technologies turned in a pretty solid second quarter for fiscal 2026, with revenue landing at $1.83 billion. That’s up 10% reported and 6.3% on a core basis, which is basically the corporate version of saying, “Yes, the engine is actually revving again.”
The profit side got a lift too
Bottom-line numbers were even kinder. GAAP net income came in at $339 million, or $1.20 a share, up from $215 million, or $0.75 a share, a year earlier. On a non-GAAP basis, Agilent made $423 million, or $1.49 a share. For a company like this, that mix of stronger sales and healthier earnings is exactly the sort of combo investors want to see before they start feeling brave again.
Why you should care
Agilent lives in the life-science and diagnostics world, so its results can act like a little temperature check for lab spending, research demand, and broader biotech-ish activity. When growth is climbing and profits are improving at the same time, it usually means customers are still spending, not hiding under the desk.
Big picture
This isn’t the kind of headline that sends traders sprinting to the exits. It’s more of a “hey, this business is still doing the job” update — the financial equivalent of a restaurant that suddenly remembers how to season the fries. And in this market, steady execution can still be a pretty big deal.